{
    "clinical_study": {
        "@rank": "8101", 
        "arm_group": [
            {
                "arm_group_label": "FOLFIRI", 
                "arm_group_type": "Active Comparator", 
                "description": "FOLFIRI regimen"
            }, 
            {
                "arm_group_label": "wXELIRI regimen", 
                "arm_group_type": "Experimental", 
                "description": "wXELIRI"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of this study is to compare weekly-XELIRI(wXELIRI) regimen versus FOLFIRI regimen in\n      the treatment of advanced colorectal cancer patients. The hypothesis is the efficacy of\n      wXELIRI is not less than FOLFIRI with tolerable toxicity."
        }, 
        "brief_title": "wXELIRI Versus FOLFIRI Regimen in the Treatment of Advanced Colorectal Cancer Patients", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Colorectal Cancer", 
        "condition_browse": {
            "mesh_term": "Colorectal Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "The combination of irinotecan and fluorouracil drugs regimen is frequently used in patients\n      with advanced colorectal cancer. According to the previous data, higher rate of diarrhea was\n      observed in the combination of irinotecan and capecitabine (XELIRI) regimen, compared to the\n      combination of irinotecan and 5-fluorouracil (FOLFIRI) regimen. However, the modified weekly\n      XELIRI regimen, which was investigated in our previous single armed study, show tolerate\n      toxicities compared with FOLFIRI, without compromising efficacy. It is supposed that wXELIRI\n      regimen is no less less than FOLFIRI regimen in efficacy."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Second-line treatment for advanced colorectal cancer,irinotecan was not  previously\n             used.\n\n          -  Age range 18-70 years old\n\n          -  ECOG performance status 0-1\n\n          -  Life expectancy of more than 3 months\n\n          -  Adequate organ function\n\n        Exclusion Criteria:\n\n          -  Previous serious cardiac disease\n\n          -  History of other malignancies except cured basal cell carcinoma of skin and\n             carcinoma in-situ of uterine cervix\n\n          -  Pregnant or lactating women\n\n          -  chronic inflammatory bowel disease or intestinal obstruction\n\n          -  Serious uncontrolled diseases and intercurrent infection"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 21, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01736904", 
            "org_study_id": "wXELIRI vs FOLFIRI in CRC"
        }, 
        "intervention": [
            {
                "arm_group_label": "wXELIRI regimen", 
                "description": "irinotecan 90mg/m2 D1, capecitabine 1000mg/m2 bid po, D1-5,repeated every 7 days", 
                "intervention_name": "wXELIRI regimen", 
                "intervention_type": "Drug", 
                "other_name": "wXELIRI"
            }, 
            {
                "arm_group_label": "FOLFIRI", 
                "description": "irinotecan 180mg/m2 d1,leucovorin 400mg/m2 d1, 5-fluorouracil 400mg/m2 iv, 2.4g/m2 civ 46h, repeated every 2 weeks", 
                "intervention_name": "FOLFIRI regimen", 
                "intervention_type": "Drug", 
                "other_name": "FOLFIRI"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "advanced colorectal cancer", 
            "FOLFIRI", 
            "XELIRI"
        ], 
        "lastchanged_date": "November 26, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China", 
                    "state": "Shanghai", 
                    "zip": "200032"
                }, 
                "name": "Fudan University Cancer Hospital"
            }, 
            "investigator": {
                "last_name": "Jin Li, PhD,MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multicenter, Randomized Phase II Study of Weekly XELIRI Regimen Versus FOLFIRI in the Treatment of Advanced Colorectal Cancer Patients", 
        "other_outcome": {
            "measure": "Overall survival which is calculated from the start to treatment to the death", 
            "safety_issue": "Yes", 
            "time_frame": "eight months"
        }, 
        "overall_contact": {
            "email": "fudanlijin@163.com", 
            "last_name": "Jin Li, PhD,MD", 
            "phone": "64175590-5109"
        }, 
        "overall_official": {
            "affiliation": "Fudan University", 
            "last_name": "Jin Lin, PhD, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Progression free survival which is calculated from the start of treatment to disease progression or death", 
            "safety_issue": "Yes", 
            "time_frame": "eight weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01736904"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Fudan University", 
            "investigator_full_name": "Jin Li", 
            "investigator_title": "Dr", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Objective response rate (ORR)= CR(complete response)+PR(partial response)", 
            "measure": "Objective response rate which includes complete response(CR) and partial response(PR) participants", 
            "safety_issue": "Yes", 
            "time_frame": "eight weeks"
        }, 
        "source": "Fudan University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Fudan University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2012"
    }
}